Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia. (vol 25, pg 30, 2006)

被引：0

|

作者：

Madhi, S. A.

Kohler, M.

Kuwanda, L.

Cutland, C.

Klugman, K. P.

机构：

来源：

PEDIATRIC INFECTIOUS DISEASE JOURNAL | 2007年 / 26卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页码：458 / 458

页数：1

相关论文

共 13 条

[1] Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia
Madhi, SA
Kohler, M
Kuwanda, L
Cutland, C
Klugman, KP
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2006, 25 (01) : 30 - 36
[2] C-reactive protein and procalcitonin in the evaluation of the efficacy of a pneumococcal conjugate vaccine in Gambian children
Cheung, Yin-Bun
Zaman, Syed M. A.
Ruopuro, Marja-Leena
Enwere, Godwin
Adegbola, Richard A.
Greenwood, Brian
Cutts, Felicity T.
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2008, 13 (05) : 603 - 611
[3] Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia
Madhi, SA
Heera, JR
Kuwanda, L
Klugman, KP
PLOS MEDICINE, 2005, 2 (02) : 147 - 151
[4] Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial (vol 365, pg 1139, 2005)
Cutts, FT
Zaman, SMA
Enwere, G
LANCET, 2005, 366 (9479): : 28 - 28
[5] Salivary C-reactive protein and mean platelet volume in diagnosis of late-onset neonatal pneumonia (vol 12, pg 1644, 2018)
Omran, A.
Ali, M.
Mhs, Mohammad
Zekry, O.
CLINICAL RESPIRATORY JOURNAL, 2020, 14 (11): : 1109 - 1109
[6] Pneumonia Hospitalizations Among Young Children Before and After Introduction of Pneumococcal Conjugate Vaccine-United States, 1997-2006 (Reprinted from MMWR, vol 58, pg 1-4, 2009)
Grijalva, C. G.
Griffin, M. R.
Nuorti, J. P.
Walter, N. D.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (12): : 1220 - 1222
[7] Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD40 ligand (vol 22, pg 691, 2006)
Liang, K-W
Sheu, W. Huey-Herng
Lee, W-L
CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 (12) : 1001 - 1001
[8] Cost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score for patients with elevated C-reactive protein(vol 110, pg 427, 2010)
MacDonald, G. P.
JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2010, 110 (09): : CP4 - CP4
[9] Association of C-reactive Protein with Early-stage Carotid Atherosclerosis in Japanese Patients with Early-state Type 2 Diabetes Mellitus (vol 53, pg 693, 2006)
Mita, Tomoya
Watada, Hirotaka
Uchino, Hiroshi
Shimizu, Tomoaki
Hirose, Takahisa
Tanaka, Yasushi
Kawamori, Ryuzo
ENDOCRINE JOURNAL, 2010, 57 (04) : 357 - 357
[10] Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial (vol 13, pg 1213, 2017)
Llorens, Xavier Saez
Rowley, Stella
Wong, Digna
Rodriguez, Mirna
Calvo, Arlene
Troitino, Marisol
Salas, Albino
Vega, Vielka
Castrejon, Maria Mercedes
Lommel, Patricia
Pascal, Thierry G.
Hausdorff, William P.
Borys, Dorota
Ruiz-Guinazu, Javier
Barrio, Eduardo Ortega
Yarzabal, Juan Pablo
Schuerman, Lode
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (03) : 928 - 930